SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is trending as the community debates its potential to break through previous highs and drop a zero amidst high social media activity. While some traders express skepticism regarding its longevity, others are actively encouraging aggressive accumulation and engagement to fuel a rally.

Dumb SEND IT

The $DSIT (Dumb SEND IT) community is aggressively pushing for a breakout, driven by the anticipation of official chart integration and a forthcoming website launch. Holders are actively engaged in community-led pump efforts and air-drop incentives, positioning the token as a resilient, community-driven play against skeptics and early profit-takers.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is currently in the spotlight following the announcement of a preliminary Phase 3 trial design for its lead candidate, CAD-1005, aimed at treating heparin-induced thrombocytopenia. While some community members are optimistic about the company's clinical pipeline and potential regulatory progress, others are expressing significant skepticism due to heavy bot-driven social media activity and concerns over the company's long-term capital needs.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is trending following media reports that GameStop is building a stake in the company as a potential acquisition target, sparking widespread debate among investors over the financial feasibility and strategic logic of a merger. Community discussions are highly polarized, with many skeptical of the deal's mechanics while others are closely tracking institutional data and potential share accumulation patterns.

Urban One, Inc. is a multi-media company, which engages in radio broadcasting that targets African-American and urban listeners. It operates through the following segments: Radio Broadcasting, Reach Media, Digital, and Cable Television. The Radio Broadcasting segment consists of all radio broadcast results of operations and low powered television operations. The Reach Media segment consists of the results of operations for the related activities and operations of the company’s syndicated shows. The Digital segment focuses on its online business, including the operations of Interactive One. The Cable Television segment deals with TV One and CLEO TV operations. The company was founded by Catherine L. Hughes in 1980 and is headquartered in Silver Spring, MD.

Urban One Inc - Ordinary Shares - Class A

Urban One Inc

Urban One is gaining traction as investors speculate on a potential rally leading up to Juneteenth, a trend that has historically drawn significant attention to the stock. The conversation is currently fueled by discussions around micro-float mechanics, recent acquisition news, and comparisons to previous parabolic moves.

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

Sanofi - ADR

Sanofi-Aventis

Sanofi is currently attracting significant investor attention as market participants speculate on the company's M&A strategy, particularly regarding potential acquisitions in the obesity, MASH, and immunology sectors. Community discourse is heavily focused on Sanofi's recent pipeline developments and the perceived need for the pharmaceutical giant to expand its portfolio to counter long-term patent cliff challenges.

Cantor Equity Partners II, Inc. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was founded on November 11, 2020 and is headquartered in New York, NY.

Cantor Equity Partners II Inc. - Ordinary Shares - Class A

Cantor Equity Partners II Inc

Cantor Equity Partners II is gaining attention as it nears its business combination with Securitize, a leading tokenization infrastructure provider that counts BlackRock and Morgan Stanley among its backers. Community sentiment is highly bullish, with investors positioning themselves in what they view as a rare pure-play opportunity to gain exposure to the emerging real-world asset tokenization market.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following reports that the company is preparing a potential takeover bid for eBay, fueling community speculation on how a strategic merger could transform the retailer into a larger e-commerce powerhouse. The stock is currently dominated by intense retail participation and heightened options activity as traders debate the viability of a large-scale acquisition, potential dilution, and the broader implications for the company's long-term growth trajectory.

Pinterest, Inc. engages in the operation of a pinboard-style photo-sharing website. It allows users to create and manage theme-based image collections such as events, interests, and hobbies. The company was founded by Benjamin Silbermann, Paul Cahill Sciarra, and Evan Sharp in October 2008 and is headquartered in San Francisco, CA.

Pinterest Inc - Ordinary Shares - Class A

Pinterest Inc

Pinterest is experiencing significant volatility as investors react to a revenue miss and cautious forward guidance, while the community actively debates whether the stock is an oversold value opportunity or a long-term play in need of new leadership. Sentiment remains divided between those betting on a technical bounce supported by the company's strong cash position and those frustrated by management's inability to capitalize on a large, active user base.

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

Seres Therapeutics is experiencing heightened investor attention driven by unusual volume and sustained price momentum, sparking renewed community discussions regarding potential buyout scenarios or strategic partnerships. Shareholders remain focused on whether this activity signals a significant corporate development ahead of upcoming fiscal windows, despite ongoing caution from some market participants wary of historical volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Mineralys Therapeutics Inc. (195% increase in followers)Radnor, Pennsylvania-based Mineralys is a clinical-stage biopharmaceutical company developing treatments for hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA), and other conditions linked to dysregulated aldosterone.Its lead candidate, lorundrostat, is an orally administered, highly selective aldosterone synthase inhibitor designed for cardiorenal conditions.Last month, Mineralys reported positive topline results from its Phase 3 Launch-HTN and Phase 2 Advance-HTN trials evaluating lorundrostat for uncontrolled and resistant hypertension. Both studies met their primary efficacy endpoints with statistical significance.&nbsp;In February, Mineralys reported a smaller-than-expected quarterly loss and disclosed that cash, cash equivalents, and investments stood at $198.2 million as of Dec. 31, 2024, which it expects to support clinical studies and corporate operations through the first quarter of 2026.The stock has gained over 28% year-to-date, with short interest at 4.5%, according to Koyfin.Sana Biotechnology Inc. (177% increase in followers)Sana focuses on developing engineered cell therapies to repair or replace damaged or missing cells, as well as control and modify genes.This year, the company has attracted significant investor interest following a potential&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sana-biotech-stock-triples-after-type-1-diabetes-trial-data/chGBWsVRZO">breakthrough</a> in type 1 diabetes. In January, it demonstrated that its hypoimmune edits enabled islet cell transplants to survive without immunosuppression, a result that drew praise from analysts.Last month, Citizens JMP upgraded Sana's stock, citing the validation of its Hypoimmune platform in type 1 diabetes, upcoming SC291 data in autoimmune diseases expected in 2025, and a strong cash position of $152.5 million. The firm considers Sana undervalued.Jefferies notes that Sana has three assets in development across different disease areas and projects peak adjusted revenues of $2.8 billion.Sana's stock is up just over 3% year-to-date, with short interest at 17.7%, according to Koyfin.Aeon Biopharma Inc. (132% increase in followers)This is a clinical-stage biopharmaceutical company developing ABP-450, a botulinum toxin complex for treating neurological conditions. Evolus markets the same botulinum toxin complex cosmetically under the name Jeuveau.ABP-450 is already approved as a biosimilar in Mexico and India. Aeon holds exclusive development and distribution rights for therapeutic indications in the U.S., Canada, the EU, the U.K., and select international markets.The stock gained attention this year following a 1-for-72 reverse stock split in March to maintain NYSE American's minimum share price requirement.Last month, Aeon announced that CEO Marc Forth would step down on April 4 to pursue another opportunity, with Chairman Jost Fischer stepping in as interim CEO.Aeon's stock has plunged over 98% year-to-date, with short interest last at 1.7%, according to Koyfin.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Mineralys, Sana, Aeon: These 3 Biotech Stocks Saw The Sharpest Retail Interest Spike In Q1

Three small-cap stocks have intrigued Stocktwits users the most among the biotech sector this year, thanks to promising data from clinical trials and a leadership shuffle.

Equity

AIM ImmunoTech, Inc. (1100% jump in message volume)AIM ImmunoTech surged in retail discussions after announcing the first new subject was dosed in Phase 2 of its Phase 1b/2 trial for Ampligen and AstraZeneca’s (AZN) Imfinzi in late-stage pancreatic cancer treatment. Several Phase 1 patients who received the highest dose will also be included in Phase 2. The trial, known as DURIPANC, is taking place in the Netherlands and will enroll up to 25 patients in this phase.PepGen, Inc. (700% jump in message volume)PepGen shares and retail chatter <a href="https://stocktwits.com/news-articles/markets/equity/pepgen-stock-heads-for-best-week-since-sept-2022/chdghv2RyH">soared</a> after the company released early clinical data from its FREEDOM-DM1 Phase 1 trial for PGN-EDODM1 in myotonic dystrophy type 1 (DM1), a genetic disorder causing progressive muscle weakness. The company reported dose-dependent splicing correction of 12.3% at 5 mg/kg and 29.1% at 10 mg/kg at 28 days post-dosing.While single-dose studies haven’t shown functional improvements, PepGen sees early signs of benefits with repeat dosing. H.C. Wainwright called the data “very encouraging.”Aeon Biopharma, Inc. (700% jump in message volume)Aeon gained attention after announcing a 1-for-72 reverse stock split to meet NYSE American’s minimum share price requirement. The move took effect on Wednesday, with fractional shares rounded up.Last month, Aeon received a non-compliance notice from NYSE American for failing to meet the $2 million stockholders’ equity requirement. The company reported a $32.1 million stockholders’ deficit as of Sept. 30 and has suffered losses in its last two fiscal years. Aeon has until March 5 to submit a plan to regain compliance.Tiziana Life Sciences Ltd. (600% jump in message volume)Tiziana’s stock buzz jumped after a Nature Neuroscience study showed its nasal anti-CD3 monoclonal antibody significantly reduced neuroinflammation and improved recovery in a preclinical model of traumatic brain injury (TBI). The treatment correlated with less anxiety, reduced cognitive decline, and improved motor skills.Additionally, Tiziana revealed on Tuesday that its nasal anti-CD3 preclinical study is nearing completion and that foralumab could be a novel treatment for long COVID.Moleculin Biotech, Inc.&nbsp;(600% jump in message volume)Moleculin saw heightened retail discussion after announcing a $1.07 per share direct offering of about 3.3 million shares and warrants to an institutional investor, with 6.5 million warrants exercisable at $1.07 per share for five years.The company&nbsp;expected to close the offering on Feb. 26, with Roth Capital Partners as the placement agent. The company said proceeds would be used for working capital and general corporate purposes.For updates and corrections, email newsroom[at]stocktwits[dot]com.

AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week

New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.

Biotech stocks remain a hot sector for retail traders on Stocktwits,&nbsp;which collectively boast over 3.45 million followers.&nbsp;In January, several biotech names saw explosive gains as investors bet on breakthrough treatments, key partnerships, and regulatory milestones.According to Stocktwits data, these five biotech stocks saw the highest surge in retail following this month.CARGO Therapeutics Inc. (CRGX) – 445% Jump In FollowersCARGO Therapeutics, a clinical-stage biotech company focused on cancer treatments, saw its stock collapse even as retail interest surged.&nbsp;In January, the FDA cleared its Investigational New Drug (IND) application for CRG-023, a novel tri-specific CAR T therapy designed to tackle relapse factors in B-cell malignancies.&nbsp;However, the company later announced it would discontinue a Phase II trial of its lead candidate, firi-cel, after an ad hoc safety analysis revealed an unfavorable benefit-risk profile.&nbsp;Wall Street analysts issued downgrades, and CARGO’s stock is on track to plunge more than 76% in January — its worst month since going public in November 2023.&nbsp;Short interest stands at 15.1%, according to Koyfin data.Sana Biotechnology Inc. (SANA) – 185% Jump In FollowersSana Biotechnology, which focuses on engineered cell therapies, captured investor attention with a potential&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sana-biotech-stock-triples-after-type-1-diabetes-trial-data/chGBWsVRZO">breakthrough</a> in type 1 diabetes.&nbsp;The company demonstrated earlier this month that its hypoimmune edits allowed islet cell transplant survival without immunosuppression.&nbsp;Analysts praised the findings, driving the stock up roughly 114% in January — its best month since its March 2021 market debut.&nbsp;Short interest is at 16.6%.Silexion Therapeutics Corp. (SLXN) – 92% Jump In FollowersSilexion, an oncology-focused biotech developing RNA interference therapies, gained momentum after releasing preclinical data on a second-generation siRNA candidate, SIL-204.&nbsp;The treatment&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/slxn-stock-hits-record-low-after-pricing-5m-offering/chGtwKoRng">showed</a> synergistic efficacy when combined with first-line chemotherapy for pancreatic cancer.&nbsp;Although the stock gained just 2% in January, it marked its best month since November.&nbsp;Short interest remains low at 2.4%.AEON Biopharma Inc. (AEON) – 81% Jump In FollowersAEON Biopharma is developing ABP-450, a botulinum toxin complex similar to Evolus’ Jeuveau, for medical indications such as chronic migraine.&nbsp;Retail traders appeared to buy the dip after AEON priced a $20 million public offering earlier this month, which initially sent shares tumbling.&nbsp;The stock is headed for a 77% drop in January, its worst month since going public via a SPAC merger in July 2023.&nbsp;Short interest is just 0.2%, according to Koyfin.Kairos Pharma (KAPA) – 78% Jump In FollowersKairos Pharma, a clinical-stage biopharmaceutical company, saw retail interest soar this month after breaking key resistance levels and securing crucial investments.&nbsp;The company is testing its lead candidate, ENV105 — which targets a protein linked to resistance in cancer treatments — in Phase 2 trials for castrate-resistant prostate cancer and Phase 1 trials for lung cancer.The stock gained momentum following CEO John Yu’s positive comments at an investor healthcare summit this month and the completion of a $3.5 million PIPE transaction.&nbsp;Kairos shares are set to decline 2.6% in January, marking their worst month since October.&nbsp;Short interest remains&nbsp;negligible at 0.1%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail Traders Flocked To These 5 Biotech Stocks In January — Here’s Why

Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.

The biotech sector remains a hotbed for retail investor interest, with over 3.4 million users following these stocks on Stocktwits. Last week, the below three companies saw the highest increases in retail following:Kairos Pharma Ltd. (+83%)Kairos Pharma, a clinical-stage biopharmaceutical company focused on cancer therapeutics, saw the most spike in retail chatter.&nbsp;The company is testing its lead candidate, ENV105 — which targets a protein linked to resistance in cancer treatments — in Phase 2 trials for castrate-resistant prostate cancer and Phase 1 trials for lung cancer.Retail interest soared last week after Kairos broke key resistance levels and secured crucial investments.&nbsp;The stock surged nearly 120% last Monday following positive comments from CEO John Yu at an investor healthcare summit.&nbsp;Additionally, the company completed a $3.5 million PIPE transaction, which the CEO said would ensure the continued progress of its clinical trials and asset development.&nbsp;Despite these gains, Kairos has lost 21% of its value since its NYSE debut in September.OS Therapies Inc. (+39%)Shares of OS Therapies jumped after the company reported positive clinical trial data for its OST-HER2 candidate, which targets a rare bone cancer that spreads to the lungs.&nbsp;Following the announcement, Maxim analyst Jason McCarthy raised the firm’s price target to $15 from $8, maintaining a ‘Buy’ rating.&nbsp;The data has positioned OS Therapies to meet with the FDA by the end of the first quarter of 2025 to discuss the possibility of filing for accelerated approval.The company is focused on oncology treatments, with OST-HER2 being its lead immunotherapy asset. It leverages listeria bacteria’s immune-stimulatory effects to target the HER2 protein in cancer cells.AEON Biopharma Inc. (+19%)AEON Biopharma is a company developing the proprietary botulinum toxin complex ABP-450, a biosimilar to Evolus’ Jeuveau, approved for cosmetic use, but AEON is developing it for medical indications.&nbsp;The company’s manufacturing partner, Daewoong, produces ABP-450 in FDA-approved facilities under current Good Manufacturing Practices (cGMP).Although there were no specific catalysts driving the recent spike, it appears that retail investors were buying the dip after the company priced a public offering to raise $20 million earlier this month, which had caused the stock to slide.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Kairos, OS Therapies, AEON See Highest Weekly Spike In Retail Following Among Biotechs: Here's Why

Cancer treatments, FDA breakthroughs, and other developments fueled a sharp spike in interest for these biotech players, as investors bet on promising clinical data and strategic moves.

AEON Biopharma, Inc. is a biopharmaceutical company, which engages in the business of developing proprietary botulinum toxin complex, ABP-450 injection, for debilitating medical conditions. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Irvine, CA.

AEON
AEON Biopharma Inc. - Ordinary Shares - Class A

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest AEON News

AEONAEON Biopharma Inc. - Ordinary Shares - Class A